Amgen announced that it will present data from several key Nplate(R) (romiplostim) studies at the 52nd Annual Meeting and Exposition of the ASH, Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of Nplate in this setting, including the final efficacy and safety results from the largest and longest study of Nplate in adult chronic ITP. Amgen will also present data for other marketed products including Neulasta(R) (pegfilgrastim) and Aranesp(R) (darbepoetin alfa).
Sean Harper, M.D., senior vice president, Global Development and Chief Medical Officer at Amgen, The complete results from a 5-year open-label extension study of Nplate in the adult chronic ITP setting show that Nplate increases and sustains platelet counts in these patients and that adverse event rates were consistent with those reported in previous studies. This is the largest and longest study of Nplate in this setting, and reinforces the potential of Nplate as a long-term treatment option.